Dianthus Therapeutics Q1 net loss $13.7M; cash $377M funds into 2H 2027

Dianthus Therapeutics, Inc. /DE/

2024-Q1 EPS reported -$0.54 revenue$874,000

Net loss $13.7M ($0.54/share) vs $7.1M ($8.10/share) in Q1 2023.
Cash, equivalents, short-term investments $377M post $230M Jan 2024 PIPE.
Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H 2025.
MMN Phase 2 trial to start Q2 2024; CIDP Phase 2 trial in 2H 2024.
R&D expense $13.1M (incl. $0.8M SBC); G&A $5.6M (incl. $1.2M SBC).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dianthus Therapeutics, Inc. /DE/ reported the quarter ended March 31, 2024 results: net income $13.7 million, EPS $0.54 net loss per share (basic and diluted).

Period: the quarter ended March 31, 2024
Net income: $13.7 million
EPS: $0.54 net loss per share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2024 was $13.7 million or $0.54 net loss per share (basic and diluted)

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-24-056925

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.